心房颤动患者中风预防的新选择
New Stroke Prophylaxis Options in Atrial Fibrillation Patients.
作者信息
Thomas George, Lerman Bruce B
机构信息
Division of Cardiology, Cornell University Medical Center, New York Presbyterian Hospital, 520 E. 70th Street, Starr 4, New York, New York 10021.
出版信息
J Atr Fibrillation. 2013 Feb 12;5(5):462. doi: 10.4022/jafib.462. eCollection 2013 Feb-Mar.
Abstract
Atrial Fibrillation (AF) is an epidemic that is increasing in size and scope. AF can have many symptoms and cause a variety of negative health impacts.The most important health risk of AF is the increased risk of stroke and systemic thromboembolism.Oral anticoagulation with warfarin has been the gold standard for stroke risk reduction in AF, but new drugs and treatment strategies for AF are changing clinical practice. These new advances could offer better tailoring of treatments to patients with high risk of stroke while reducing the potential bleeding complications.
摘要
心房颤动（AF）是一种规模和范围都在不断扩大的流行病。AF可能有多种症状，并会对健康造成各种负面影响。AF最重要的健康风险是中风和全身性血栓栓塞风险增加。使用华法林进行口服抗凝一直是降低AF中风风险的金标准，但AF的新药和治疗策略正在改变临床实践。这些新进展可以为中风高危患者提供更个性化的治疗，同时减少潜在的出血并发症。
相似文献
1
New Stroke Prophylaxis Options in Atrial Fibrillation Patients.心房颤动患者中风预防的新选择
J Atr Fibrillation. 2013 Feb 12;5(5):462. doi: 10.4022/jafib.462. eCollection 2013 Feb-Mar.
2
Prevention of stroke in patients with atrial fibrillation.心房颤动患者的卒中预防
Semin Vasc Med. 2005 Aug;5(3):285-92. doi: 10.1055/s-2005-916168.
3
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.新型口服抗凝药物在房颤卒中预防中的应用：重点关注阿哌沙班。
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7.
5
Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.新型抗血栓治疗在预防心房颤动患者心源性栓塞并发症中的作用。
Am J Cardiovasc Drugs. 2011 Aug 1;11(4):265-75. doi: 10.2165/11592410-000000000-00000.
6
Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.不同抗凝管理的房颤导管消融患者围术期卒中与出血并发症：来自华法林在房颤（AF）患者导管消融中预防血栓栓塞（COMPARE）随机试验的作用（Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation （AF） Patients Undergoing Catheter Ablation，COMPARE）的研究结果。
Circulation. 2014 Jun 24;129(25):2638-44. doi: 10.1161/CIRCULATIONAHA.113.006426. Epub 2014 Apr 17.
7
Guidelines for stroke prevention in patients with atrial fibrillation.心房颤动患者卒中预防指南。
Drugs. 1999 Dec;58(6):997-1009. doi: 10.2165/00003495-199958060-00004.
8
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).不同类型心房颤动患者的卒中与死亡风险：来自 ENGAGE AF-TIMI 48 试验（新型 Xa 因子抗凝在心房颤动-心肌梗死溶栓 48 中的疗效）的结果。
Circ Arrhythm Electrophysiol. 2017 Jan;10(1). doi: 10.1161/CIRCEP.116.004267.
9
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).与新型口服抗凝药用于新发房颤患者预防卒中相关的因素：房颤更好知情治疗结局登记研究II（ORBIT-AF II）的结果
Am Heart J. 2017 Jul;189:40-47. doi: 10.1016/j.ahj.2017.03.024. Epub 2017 Apr 4.
10
Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.心房颤动中的卒中：病理生理学、新型抗栓治疗以及手术和器械进展的最新情况
Ann Med. 2007;39(5):371-91. doi: 10.1080/07853890701320662.
本文引用的文献
1
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.在健康受试者中，用凝血酶原复合物浓缩物逆转利伐沙班和达比加群：一项随机、安慰剂对照、交叉研究。
Circulation. 2011 Oct 4;124(14):1573-9. doi: 10.1161/CIRCULATIONAHA.111.029017. Epub 2011 Sep 6.
2
Apixaban versus warfarin in patients with atrial fibrillation.阿哌沙班与华法林用于房颤患者。
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
3
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
4
Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring.使用连续心律失常负担监测改善阵发性心房颤动患者的 CHADS2 和 CHA2DS2-VASc 风险评分进行卒中风险分层。
Stroke. 2011 Jun;42(6):1768-70. doi: 10.1161/STROKEAHA.110.609297. Epub 2011 Apr 14.
5
Apixaban in patients with atrial fibrillation.阿哌沙班用于房颤患者。
N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432. Epub 2011 Feb 10.
6
Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.验证用于预测心房颤动患者中风和血栓栓塞风险分层方案的有效性：全国队列研究。
BMJ. 2011 Jan 31;342:d124. doi: 10.1136/bmj.d124.
7
Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.新型抗凝药物在房颤卒中预防中的应用：当前的临床证据与未来进展。
J Am Coll Cardiol. 2010 Dec 14;56(25):2067-76. doi: 10.1016/j.jacc.2010.09.017.
8
Effect of home testing of international normalized ratio on clinical events.家庭凝血酶原时间国际标准化比值检测对临床事件的影响。
N Engl J Med. 2010 Oct 21;363(17):1608-20. doi: 10.1056/NEJMoa1002617.
9
Stroke risk and antithrombotic strategies in atrial fibrillation.心房颤动的卒中风险与抗栓策略。
Stroke. 2010 Nov;41(11):2705-13. doi: 10.1161/STROKEAHA.110.589218. Epub 2010 Oct 7.
10
An evaluation of the CHADS₂ stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization.经皮冠状动脉血运重建术治疗的心房颤动患者中 CHADS₂ 卒中风险评分的评估。
Chest. 2011 Jun;139(6):1402-1409. doi: 10.1378/chest.10-1408. Epub 2010 Sep 23.
Zotero 插件